Molecular taxonomy of myelodysplastic syndromes and its clinical implications.
Bernard E. et al, (2024), Blood, 144, 1617 - 1632
Hyperactivation of NF-κB signaling in splicing factor mutant myelodysplastic syndromes and therapeutic approaches.
Pellagatti A. and Boultwood J., (2024), Adv Biol Regul
Molecular and clinical presentation of UBA1-mutated myelodysplastic syndromes.
Sirenko M. et al, (2024), Blood, 144, 1221 - 1229
Splicing factor mutations in the myelodysplastic syndromes: Role of key aberrantly spliced genes in disease pathophysiology and treatment.
Pellagatti A. and Boultwood J., (2022), Adv Biol Regul
Activation of targetable inflammatory immune signaling is seen in myelodysplastic syndromes with SF3B1 mutations.
Choudhary GS. et al, (2022), Elife, 11
Pathophysiologic and clinical implications of molecular profiles resultant from deletion 5q.
Adema V. et al, (2022), EBioMedicine, 80
PRELIMINARY PROSPECTIVE MOLECULAR ANALYSIS OF PLCBETA1 AND PLCGAMMA2 IN MDS PATIENTS TREATED WITH AZACITIDINE AND VENETOCLAX
De Stefano A. et al, (2022), HAEMATOLOGICA, 107, 65 - 65
ASXL1 mutations are associated with distinct epigenomic alterations that lead to sensitivity to venetoclax and azacytidine
Rahmani NE. et al, (2021), Blood Cancer Journal, 11
Author Correction: Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes.
Bernard E. et al, (2021), Nat Med, 27
MDMX acts as a pervasive preleukemic-to-acute myeloid leukemia transition mechanism.
Ueda K. et al, (2021), Cancer Cell
Author Correction: Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes.
Bernard E. et al, (2021), Nat Med, 27
The utilisation of glutamine and glucose by a 3-D tumour model trapped in quiescence.
Smith H. et al, (2021), Int J Biochem Cell Biol
SF3B1 mutant myelodysplastic syndrome: Recent advances.
Pellagatti A. and Boultwood J., (2020), Adv Biol Regul
Sequential Analysis of miRNA Profiling during Azacitidine and Lenalidomide Therapy in Myelodysplastic Syndromes
Follo MY. et al, (2020), BLOOD, 136
DEFERASIROX TARGETS PHOSPHOLIPASE C BETA1 SIGNALING IN MYELODYSPLASTIC SYNDROMES (MDS)
Follo MY. et al, (2020), HAEMATOLOGICA, 105, S63 - S63
Spliceosome mutations: 1 plus 1 does not always equal 2.
Pellagatti A. and Boultwood J., (2020), Blood, 136, 1471 - 1472